Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 12, 2015, 64 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $46,952,213.79.

Highlighted Stocks Traded by Insiders:

Rudolph Technologies (RTEC) - FREE Research Report

Roth Steven R, who is Senior Vice President & CFO at Rudolph Technologies, sold 10,000 shares at $12.44 on Feb. 12, 2015. Following this transaction, the Senior Vice President & CFO owned 84,063 shares meaning that the stake was reduced by 10.63% with the 10,000-share transaction.

Colgan Michael J., who is Shareholder at Rudolph Technologies, sold 5,112 shares at $12.54 on Feb. 12, 2015. Following this transaction, the Shareholder owned 25,045 shares meaning that the stake was reduced by 16.95% with the 5,112-share transaction.

The shares most recently traded at $12.25, down $0.29, or 2.38% since the insider transaction. Historical insider transactions for Rudolph Technologies go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 8,000
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 19,000

The average volume for Rudolph Technologies has been 249,000 shares per day over the past 30 days. Rudolph Technologies has a market cap of $406.9 million and is part of the technology sector and electronics industry. Shares are up 20.33% year-to-date as of the close of trading on Thursday.

Rudolph Technologies, Inc. designs, develops, manufactures, and supports process control defect inspection, advanced packaging lithography, metrology, and process control software systems used in semiconductor device manufacturing. The company has a P/E ratio of 39.5. Currently, there are 4 analysts who rate Rudolph Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RTEC - FREE

TheStreet Quant Ratings

rates Rudolph Technologies as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Rudolph Technologies Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Pfizer (PFE) - FREE Research Report

Damelio Frank A, who is Executive Vice President at Pfizer, sold 95,000 shares at $34.24 on Feb. 12, 2015. Following this transaction, the Executive Vice President owned 360,686 shares meaning that the stake was reduced by 20.85% with the 95,000-share transaction.

The shares most recently traded at $34.84, up $0.60, or 1.73% since the insider transaction. Historical insider transactions for Pfizer go as follows:

  • 4-Week # shares sold: 6,500
  • 12-Week # shares sold: 6,500
  • 24-Week # shares sold: 69,669

The average volume for Pfizer has been 28.1 million shares per day over the past 30 days. Pfizer has a market cap of $215.8 billion and is part of the health care sector and drugs industry. Shares are up 11.94% year-to-date as of the close of trading on Thursday.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The stock currently has a dividend yield of 3.27%. The company has a P/E ratio of 21.1. Currently, there are 9 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PFE - FREE

TheStreet Quant Ratings

rates Pfizer as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Pfizer Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Albany Molecular Research (AMRI) - FREE Research Report

D Ambra Constance M, who is 10% Owner at Albany Molecular Research, sold 20,000 shares at $16.91 on Feb. 12, 2015. Following this transaction, the 10% Owner owned 2.5 million shares meaning that the stake was reduced by 0.79% with the 20,000-share transaction.

D Ambra Thomas E Phd, who is Chairman, Board of Directors at Albany Molecular Research, sold 20,000 shares at $16.91 on Feb. 12, 2015. Following this transaction, the Chairman, Board of Directors owned 2.7 million shares meaning that the stake was reduced by 0.75% with the 20,000-share transaction.

The shares most recently traded at $17.00, up $0.09, or 0.53% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 40,000
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 80,000
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 203,500

The average volume for Albany Molecular Research has been 538,800 shares per day over the past 30 days. Albany Molecular Research has a market cap of $554.3 million and is part of the health care sector and drugs industry. Shares are up 5.77% year-to-date as of the close of trading on Thursday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 141.7. Currently, there are 2 analysts who rate Albany Molecular Research a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings

rates Albany Molecular Research as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full

Albany Molecular Research Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null